Evidence map›Paper›PMID 41088317›Full record

ArticleBMC pharmacology & toxicology2025

Quality analysis of albendazole formulations available in veterinary pharmacies of Nepal.

Sujeeta Pokharel Dhakal, Binita Acharya, Sujan Rana, Shashidhar Sedhai, Salina Manandhar

Abstract read
In one paragraph

Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sujeeta Pokharel DhakalVeterinary Standards and Drug Regulatory Laboratory, Kathmandu, Nepal. Pokharel.sujeeta.vet@gmail.com.ORCID 0000-0002-6051-1350
Binita AcharyaVeterinary Standards and Drug Regulatory Laboratory, Kathmandu, Nepal.
Sujan RanaVeterinary Standards and Drug Regulatory Laboratory, Kathmandu, Nepal.
Shashidhar SedhaiVeterinary Standards and Drug Regulatory Laboratory, Kathmandu, Nepal.
Salina ManandharVeterinary Standards and Drug Regulatory Laboratory, Kathmandu, Nepal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEcto- and endoparasites cause significant economic losses to the livestock industry, primarily due to helminth parasites. The heavy reliance on anthelmintics to control parasites, coupled with inadequate drug quality in terms of physical and content parameters, often leads to excessive and irrational use of anthelmintics. This poses a public health hazard due to the potential development of anthelmintic resistance. The dosage prescribed depends on the active ingredients present in the drug. Thus, an anthelmintic drug must contain the labeled amount of active pharmaceutical ingredients and comply with the standard quality tests. Veterinary Standards and Drug Regulatory Laboratory (VSDRL) is the national regulatory laboratory of Nepal for veterinary products, mandated to test the quality of various veterinary drugs. Amidst growing concerns of anthelmintic resistance and constant rumors of ineffectiveness of anthelmintics in the Nepalese market, it is vital to analyze the quality of veterinary drugs in Nepal. This study aims to analyze the quality (physical and content analysis) of albendazole drug available in the local market and to aware the general public, veterinary practitioners, and policy makers.

methodsWe conducted the study from July 2021 to July 2023 at VSDRL in Kathmandu. A total of 118 samples of albendazole drug (suspension of 25 mg/ml, tablets of 200 mg and 300 mg, and boluses of 600 mg and 1500 mg) were collected from seven different pharmaceuticals across 20 districts of Nepal. The samples were tested for their physical conformity and assay according to the laboratory protocols of VSDRL. Physical analysis included weight variation, hardness, friability, and disintegration, whereas the content analysis was performed using UV spectrophotometry and High-performance liquid chromatography (HPLC). Data were entered and analyzed using MS Excel and visualized with R.

resultsAll samples complied with standard limits for weight variation, disintegration time ( < 15 min), and API content (tablets/boluses: 92.5–107.5%; suspension: 90–110%). However, only 46% and 20% of tablets/boluses of company B and A respectively, met the standard hardness range (5–10 kg/cm2). Most of the samples had higher hardness than the standard limit, although all samples complied with the standard disintegration time. Friability compliance varied with highest percentage of compliance of company C. However, the Fisher’s Exact Test did not show a significant association between companies and friability compliance (p = 0.379).

conclusionThus, it is necessary to routinely monitor the quality of veterinary drugs to ensure that they are manufactured and supplied to the market as per the recommended standards, thereby safeguarding both animal and public health.

Indexed as

AlbendazoleAnthelminticsVeterinary DrugsAnimalsBulk DrugsChemistry, PharmaceuticalNepalQuality ControlAlbendazoleAnthelminticsBulk DrugsVeterinary DrugsAlbendazoleDrug qualityNepalPhysical and content analysisVSDRL

Identifiers

PMID41088317
PMCPMC12522781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.